Clinical Trial Update: Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial investigating rituximab for progression of humoral acute rejection in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection in Kidney Transplantation

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Graft Rejection | Phase 3 | Status: UNKNOWN